Today TRINITY published a white paper exploring the truth of reimbursement challenges for cell and gene therapies (CGTs). In recent years, we have seen cell and gene therapies (CGTs) morph from a small niche into one of the most exciting markets in biopharma. We are fast approaching an inflection point when many CGTs will gain approval and offer clinical benefits for areas of high unmet need. This development is positive for patients with rare diseases, and the insurance market will need to be restructured to facilitate the arrival of these therapies. This new white paper explores the truth of reimbursement challenges for CGTs through payer research and economic analysis, highlighting key misconceptions of the unique challenges facing CGTs in reimbursement. Key Insights Include:
- Given current trends in the CGT market (e.g. number of CGTs, prices, target populations), the current reimbursement model is rapidly becoming unsustainable
- Misunderstanding of payers’ needs and situation leading to misguided focus of manufacturers entering this space
- Revolution in reimbursement model is needed if CGT market expansion is significant
Please see the full white paper here: https://trinitylifesciences.com/thought-leadership/exploring-the-truth-of-reimbursement-challenges-for-cell-and-gene-therapies/
TRINITY is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, TRINITY is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights.
TRINITY’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS. TRINITY, together with its subsidiary TGaS® Advisors, has 5 offices throughout the US, including Boston, New York, Princeton, Philadelphia, and San Francisco as well as Toronto, Canada, and Gurgaon, India. TRINITY will be opening its first European Office on July 1, 2019 in Munich, Germany. To learn more about how TRINITY is elevating life sciences and driving from evidence to action, visit trinitylifesciences.com